Comparative Pharmacology
Head-to-head clinical analysis: CHIROCAINE versus DENTIPATCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHIROCAINE versus DENTIPATCH.
CHIROCAINE vs DENTIPATCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chirocaine (levobupivacaine) is a long-acting local anesthetic of the amide type. It blocks sodium channels, inhibiting nerve impulse initiation and conduction, thereby producing local anesthesia.
Local anesthetic agent that inhibits sodium ion influx into nerve cells, blocking nerve conduction and pain sensation.
0.5% to 0.75% solution; epidural: 10-20 mL of 0.5% solution (50-100 mg) as initial dose; for surgical anesthesia, 15-20 mL of 0.75% solution (112.5-150 mg); repeat doses of 0.25% to 0.5% solution at 40-60 minute intervals as needed. Maximum single dose: 225 mg.
Apply one 10 mg/10 cm² transdermal patch to intact skin once daily, typically in the morning; remove after 24 hours and replace with a new patch.
None Documented
None Documented
Terminal elimination half-life is 0.5–1.5 hours (adults) and 1–2 hours (neonates). Clinically, this short half-life limits accumulation with repeated doses.
Terminal elimination half-life is approximately 7–9 hours; clinically, steady-state is achieved after 2–3 days of daily application.
Renal excretion accounts for approximately 95% of the dose, with most being eliminated as metabolites (mainly p-aminobenzoic acid and other conjugates) and less than 5% as unchanged drug. Biliary/fecal excretion is minimal (<5%).
Approximately 60% of the dose is excreted renally as unchanged drug and metabolites; the remainder is eliminated via biliary/fecal routes.
Category C
Category C
Local Anesthetic
Local Anesthetic